MEDPNasdaqServices-Commercial Physical & Biological ResearchFiscal year ends December 31
Medpace Holdings, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Oct 22, 2026
$619.66+1.19 (+0.19%)
Close on Oct 19, 2026
- Market cap
- $17.69B
- P/E (TTM)
- 36.3
- Dividend yield
- –
Medpace Holdings, Inc. revenue by segment
By business segment
By product or service
| Revenue | Q2 26 | Q1 26 | Q4 25 | Q3 25 | Q2 25 | Q1 25 | Q4 24 | Q3 24 | Q2 24 | Q1 24 | Q4 23 | Q3 23 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Other | $219.07M | $237.56M | $249.81M | $199.26M | $147.87M | $148.02M | $122.87M | $124.73M | $106.30M | $103.64M | $99.02M | $103.12M | 31.0% | +48.1% |
| Metabolic | $209.37M | $201.24M | $195.92M | $192.64M | $188.56M | $170.48M | $168.17M | $164.92M | $162.95M | $155.20M | $148.73M | $149.33M | 29.6% | +11.0% |
| Oncology | $98.28M | $93.32M | $88.25M | $106.40M | $118.06M | $95.84M | $103.18M | $107.37M | $112.43M | $108.40M | $110.53M | $106.16M | 13.9% | -16.8% |
| Cardiology | $82.86M | $80.21M | $73.18M | $65.63M | $61.13M | $54.90M | $49.22M | $42.10M | $46.52M | $44.14M | $39.65M | $43.99M | 11.7% | +35.5% |
| Central Nervous System | $59.98M | $56.26M | $63.04M | $59.47M | $58.58M | $58.28M | $58.30M | $55.81M | $60.70M | $55.64M | $51.58M | $44.36M | 8.5% | +2.4% |
| AVAI | $37.77M | $38.02M | $38.25M | $36.52M | $29.11M | $31.06M | $34.84M | $38.38M | $39.20M | $44.03M | $48.89M | $45.55M | 5.3% | +29.8% |
| Revenue net | – | – | – | – | – | – | – | – | – | – | $498.40M | $492.50M | – | – |
By region
From the segment and revenue-disaggregation notes of Medpace's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.